{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:18:00Z","timestamp":1778591880367,"version":"3.51.4"},"reference-count":7,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Dear Editor,\nMogamulizumab is a humanized, defucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4), expressed on malignant T cells in cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides and S\u00e9zary syndrome. By enhancing antibody-dependent cellular cytotoxicity, mogamulizumab selectively depletes CCR4-positive malignant lymphocytes and has demonstrated significant clinical activity in advanced CTCL, including in patients refractory to multiple prior therapies. [...]<\/jats:p>","DOI":"10.4081\/dr.2026.10823","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:00:57Z","timestamp":1778590857000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of mogamulizumab in S\u00e9zary syndrome with concomitant Crohn\u2019s disease"],"prefix":"10.4081","author":[{"given":"Cosimo","family":"Di Raimondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Mortato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Paolo","family":"Di Domenico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"40097","doi-asserted-by":"crossref","unstructured":"1. Fern\u00e1ndez-Guarino M, Ortiz P, Gallardo F, Llamas-Velasco M. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review. Int J Mol Sci 2024;25:2203.","DOI":"10.3390\/ijms25042203"},{"key":"40098","doi-asserted-by":"crossref","unstructured":"2. Choi SB, Lee HT, Gu N, et al. Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma. Int J Mol Sci 2025;26:5500.","DOI":"10.3390\/ijms26125500"},{"key":"40099","doi-asserted-by":"crossref","unstructured":"3. Martinez XU, Di Raimondo C, Abdulla FR, et al. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and S\u00e9zary syndrome. Best Pract Res Clin Haematol 2019;32:239-52.","DOI":"10.1016\/j.beha.2019.06.004"},{"key":"40100","unstructured":"4. Kim YH, Bagot M, Pinter-Brown L, et al; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, openlabel, randomised, controlled phase 3 trial. Lancet Oncol 2018;19:1192-204. Erratum in: Lancet Oncol 2018;19:e581."},{"key":"40101","doi-asserted-by":"crossref","unstructured":"5. Blanchard G, Blanchard M, Bernard P, et al. Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management. JAAD Case Rep 2024;54:23-6.","DOI":"10.1016\/j.jdcr.2024.09.021"},{"key":"40102","doi-asserted-by":"crossref","unstructured":"6. Kunkel EJ, Boisvert J, Murphy K, et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol 2002;160:347-55.","DOI":"10.1016\/S0002-9440(10)64378-7"},{"key":"40103","doi-asserted-by":"crossref","unstructured":"7. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-80.","DOI":"10.1038\/23495"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10823\/9933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10823\/9933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:01:16Z","timestamp":1778590876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":7,"URL":"https:\/\/doi.org\/10.4081\/dr.2026.10823","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}